CATALYST PHARMACEUTICALS INC (CPRX) Stock Price, Quote, News and Overview
NASDAQ:CPRX - Nasdaq - US14888U1016 - Common Stock - Currency: USD
CPRX Quote, Performance and Key Statistics
21.62
-0.43 (-1.95%)
The current stock price of CPRX is 21.62 USD. In the past month the price decreased by -3.95%. In the past year, price increased by 53.99%.
CPRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CPRX
Company Profile
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 167 full-time employees. The company went IPO on 2006-11-08. The firm is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The firm is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Company Info
CATALYST PHARMACEUTICALS INC
355 Alhambra Circle, Suite 801
Coral Gables FLORIDA 33134 US
CEO: Patrick J. McEnany
Employees: 167
Company Website: https://catalystpharma.com/
Investor Relations: https://ir.catalystpharma.com/
Phone: 13055292522
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the stock price of CATALYST PHARMACEUTICALS INC today?
The current stock price of CPRX is 21.62 USD. The price decreased by -1.95% in the last trading session.
What is the ticker symbol for CATALYST PHARMACEUTICALS INC stock?
The exchange symbol of CATALYST PHARMACEUTICALS INC is CPRX and it is listed on the Nasdaq exchange.
On which exchange is CPRX stock listed?
CPRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CATALYST PHARMACEUTICALS INC stock?
14 analysts have analysed CPRX and the average price target is 33.41 USD. This implies a price increase of 54.51% is expected in the next year compared to the current price of 21.62. Check the CATALYST PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CATALYST PHARMACEUTICALS INC worth?
CATALYST PHARMACEUTICALS INC (CPRX) has a market capitalization of 2.58B USD. This makes CPRX a Mid Cap stock.
How many employees does CATALYST PHARMACEUTICALS INC have?
CATALYST PHARMACEUTICALS INC (CPRX) currently has 167 employees.
What are the support and resistance levels for CATALYST PHARMACEUTICALS INC (CPRX) stock?
CATALYST PHARMACEUTICALS INC (CPRX) has a support level at 20.66 and a resistance level at 23.93. Check the full technical report for a detailed analysis of CPRX support and resistance levels.
Is CATALYST PHARMACEUTICALS INC (CPRX) expected to grow?
The Revenue of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 23.03% in the next year. Check the estimates tab for more information on the CPRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CATALYST PHARMACEUTICALS INC (CPRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CPRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CPRX, evaluating the profitability, health, valuation and growth aspects
- CATALYST PHARMACEUTICALS INC (CPRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CATALYST PHARMACEUTICALS INC (CPRX) Sales and EPS estimates to see what analysts future expectations are.
- CATALYST PHARMACEUTICALS INC (CPRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CATALYST PHARMACEUTICALS INC (CPRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CATALYST PHARMACEUTICALS INC (CPRX) Stock Chart to make your own analysis
- CATALYST PHARMACEUTICALS INC (CPRX) Latest news and press-releases to stay up to date.
Does CATALYST PHARMACEUTICALS INC (CPRX) stock pay dividends?
CPRX does not pay a dividend.
When does CATALYST PHARMACEUTICALS INC (CPRX) report earnings?
CATALYST PHARMACEUTICALS INC (CPRX) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of CATALYST PHARMACEUTICALS INC (CPRX)?
The PE ratio for CATALYST PHARMACEUTICALS INC (CPRX) is 18.32. This is based on the reported non-GAAP earnings per share of 1.18 and the current share price of 21.62 USD. Check the full fundamental report for a full analysis of the valuation metrics for CPRX.
What is the Short Interest ratio of CATALYST PHARMACEUTICALS INC (CPRX) stock?
The outstanding short interest for CATALYST PHARMACEUTICALS INC (CPRX) is 4.8% of its float. Check the ownership tab for more information on the CPRX short interest.
CPRX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CPRX. When comparing the yearly performance of all stocks, CPRX is one of the better performing stocks in the market, outperforming 89.3% of all stocks.
CPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to CPRX. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
CPRX Financial Highlights
Over the last trailing twelve months CPRX reported a non-GAAP Earnings per Share(EPS) of 1.18. The EPS increased by 63.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.01% | ||
| ROA | 18.5% | ||
| ROE | 21.61% | ||
| Debt/Equity | 0 |
CPRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to CPRX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 53.09% and a revenue growth 23.03% for CPRX